Ann: Positive IHL-675A in vivo results and FDA Pathway, page-123

It looks like MSB does have other therapies in development.
The selloff may turn out to have been an overreaction there, but it is definitely a sobering reminder that chasing a covid remedy is a double-edged sword. The perception can be that failure in that arena is a more dire indictment of the company than it actually is: covid is almost all that matters to some people right now, and it is easy for them to focus on it to the exclusion of most other value within the company.

I do think IHL is in a much better position overall, compared to MSB, in terms of sentiment and outlook.
My condolences to those who were invested in MSB.